Biosimilar

Biological medicines are made in living systems, so they cannot be copied exactly the way a conventional generic copies a small-molecule drug. A biosimilar is approved on the basis that it is highly similar to an already-approved reference product and has no clinically meaningful differences from it in safety, purity, or potency.

Some biosimilars are additionally designated interchangeable, which bears on whether a pharmacist may substitute without consulting the prescriber. Those rules vary by jurisdiction.

What patients ask your team

• Whether a biosimilar is the same as their current medicine.
• Why their plan now prefers a different product.
• Whether they should switch.

Why it matters to your program

Biosimilars often enter the conversation through cost — a plan may prefer one over the reference product on its formulary — and the patient’s question quickly becomes a clinical one that belongs with the prescriber.

How OpenSupport handles it

The assistant defines the terms with citations to the regulator. It does not recommend switching or staying: whether a switch is appropriate is a clinical decision, and the assistant’s answer guardrails screen out directive and diagnostic language.